Background

The first large-scale evaluation of prescribing patterns for imported fire ant (IFA) in a large US health care system was published by Haymore et al in 2009. In this first evaluation of prescriptions from 1990 to 2007, the most often prescribed maintenance IFA prescription was 0.5 mL of 1:200 wt/vol.

Objective

To provide an updated description of IFA prescribing patterns over the ensuing 11 years from same large health care system.

Methods

We reviewed 1349 new IFA prescriptions written from 2007 to 2018, from a large nationwide health care system, with primary end points being maintenance prescription strength and prescribing patterns.

Results

In comparison to the data published by Haymore et al in 2009, which reported that 17% of the prescriptions were written for 0.5 mL of 1:100 wt/vol maintenance, we found that 69% (95% CI: 66.4%-71.4%) of IFA prescriptions written in the past 11 years were for the maintenance concentration of 0.5 mL of 1:100 wt/vol. We further studied the linear trend over time of percentage of prescriptions written for individual concentrations and observed that the percentage of 1:100 wt/vol prescriptions increased 3.5% yearly (R² = 0.68, P < .001) from 2007 (40.0%, 95% CI: 24.6%-57.7%) to 2018 (84.4%, 95% CI: 77.4%-89.5%).

Conclusion

Our study shows significant improvement in the accuracy and precision of IFA immunotherapy dosing for patients with IFA hypersensitivity, with ascendancy of 0.5 mL 1:100 wt/vol as the predominant treatment dose. A total of 87% of patients within our study were treated within the parameter recommendations, a stark improvement from findings in the 2009 Haymore study.

中文翻译：

---

在大型医疗保健系统中，在11年内采用了进口的火蚁免疫疗法处方模式。

背景

Haymore等人于2009年发布了在大型美国医疗保健系统中对进口火蚁（IFA）的处方模式进行的首次大规模评估。在1990年至2007年的首次处方评估中，最常用的维持IFA处方处方0.5mL的1：200wt / vol。

目的

在同一大型卫生保健系统的随后11年中，对IFA处方模式进行更新描述。

方法

我们审查了2007年至2018年间来自大型全国卫生保健系统的1349份新的IFA处方，主要终点是维持处方强度和处方模式。

结果

与Haymore等人在2009年发布的数据相比，该数据报告17％的处方是按0.5 mL 1：100 wt / vol的剂量配制的，我们发现69％（95％CI：66.4％-71.4％ ）在过去11年中制定的IFA处方的维持浓度为0.5 mL 1：100 wt / vol。我们进一步研究了针对各个浓度的处方百分比随时间的线性趋势，并观察到1：100 wt / vol处方的百分比与2007年（40.0％，2007年）相比每年增加3.5％（R ²  = 0.68，P <.001）。 95％CI：24.6％-57.7％）至2018年（84.4％，95％CI：77.4％-89.5％）。

结论

我们的研究显示，对于IFA过敏症患者，IFA免疫疗法给药的准确性和精密度有了显着提高，以0.5 mL 1：100 wt / vol的上升剂量作为主要治疗剂量。我们的研究中总共有87％的患者在参数建议范围内接受了治疗，这与2009年Haymore研究中的发现相比有明显改善。